Dec 27, 2022 – Axcynsis Therapeutics has been awarded “TOP 5 Biotech Startups in Singapore 2022” by Startup City APAC Magazine.

Startup City is a San Francisco-based leading media source where investors and technology decision-makers share their wisdom, knowledge, and technological expertise, following a unique learn-from-peers approach.

“We are thankful for this recognition and for being featured in the December issue of Startup City APAC Magazine. We will continue to work hard towards our goal in becoming a global leading AXC company.” says Dr Zou, CEO of Axcynsis Therapeutics.



About Axcynsis Therapeutics Pte. Ltd.
Axcynsis Therapeutics Pte. Ltd. is a platform-based biotechnology company focusing on the development of Antibody-X Conjugate (AXC) therapies to revolutionise cancer treatments. Leveraging on proprietary technologies, we are developing a robust pipeline of AXC candidates with the potential to address unmet medical needs for new treatment options.

For all media queries, please contact:
Wong Yun Xuan
Operations Manager
T: 65502963